AstraZeneca’s (AZN) Calquence in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukaemia and small lymphocytic lymphoma. The approval by the US Food and Drug Administration, FDA, was based on positive results from the AMPLIFY Phase III trial, which were presented at the American Society of Hematology 2024 Annual Meeting and published in The New England Journal of Medicine.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca wins U.S. nod for first fixed-duration all-oral CLL combo
- AstraZeneca Pauses Real‑World NMOSD Study in Russia, Keeping Near‑Term Stock Impact Limited
- AstraZeneca’s Calquence Japan Safety Study Wraps Up, Clarifying Real-World Risk for AZN Investors
- AstraZeneca marketing authorization application for Enhertu validated by EMA
- FDA to begin requiring on clinical trial